Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

1 Mar 1992

Abstract excerpt

Due to its remarkably long half-life, together with its wide in vivo distribution and its lack of enzymatic or immunological functions, human serum albumin (HSA) represents an optimal carrier for therapeutic peptides/proteins aimed at interacting with cellular or molecular components of the vascular and interstitial compartments. As an example, we designed a genetically engineered HSA-CD4 hybrid aimed at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Toxin Mechanisms and Immunotoxins
Share to Transgenic Plants and Applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 1542690
DOI: 10.1073/pnas.89.5.1904

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.PMID 1542690Read ↗

Structural conservation and expanded functionality of hyper-stable human serum albumin variantsSemantic proximity Read ↗

Pharmaceutical strategies utilizing recombinant human serum albumin.Semantic proximity Read ↗

Crystal structure of human serum albumin in complex with megabody reveals unique human and murine cross‐reactive binding siteSemantic proximity Read ↗

Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding DomainSemantic proximity Read ↗

Development and characterization of fused human arginase I for cancer therapySemantic proximity Read ↗

Selection of phage‐displayed llama single‐domain antibodies that transmigrate across human blood‐brain barrier endotheliumSemantic proximity Read ↗

Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokineticsSemantic proximity Read ↗

Fusion of a Short Peptide that Binds Immunoglobulin G to a Recombinant Protein Substantially Increases Its Plasma Half-Life in MiceSemantic proximity Read ↗

Half-life extension using serum albumin-binding DARPin® domainsSemantic proximity Read ↗

Gas vesicle-blood interactions enhance ultrasound imaging contrastSemantic proximity Read ↗

In Vivo Study of Newly Developed Albumin-Conjugated Urate Oxidase for Gout TreatmentSemantic proximity Read ↗

Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.